Match!
Young Jun Chang
Seoul National University
121Publications
19H-index
1,222Citations
Publications 121
Newest
#1Jun Sik Yoon (Inje University)
#2Byeong Geun Song (SMC: Samsung Medical Center)H-Index: 1
Last.Dong Hyun Sinn (SMC: Samsung Medical Center)H-Index: 19
view all 10 authors...
Background Several randomized controlled trials have shown that adjuvant immunotherapy with autologous cytokine-induced killer (CIK) cells prolongs recurrence-free survival (RFS) after curative treatment for hepatocellular carcinoma (HCC). We investigated the efficacy of adjuvant immunotherapy with activated CIK cells in real-world clinical practice.
#1Yun Bin Lee (SNU: Seoul National University)H-Index: 8
#2Joon Yeul Nam (SNU: Seoul National University)H-Index: 4
Last.Deok Hee Lee (SNU: Seoul National University)H-Index: 51
view all 10 authors...
#1Xuefei Zhou (Fudan University)
#2Ziao Tian (CAS: Chinese Academy of Sciences)H-Index: 4
Last.Yongfeng Mei (Fudan University)H-Index: 41
view all 10 authors...
#1Young Jun ChangH-Index: 19
#2Yuri ChoH-Index: 12
Last.Nam-Joon YiH-Index: 31
view all 10 authors...
Background and Aims: Several models have been developed to predict tumor the recurrence of hepatocellular carcinoma (HCC) after liver transplantation besides the conventional Milan criteria (MC), including the MoRAL score. This study aimed to compare the prognostication power of the MoRAL score to most models designed so far in the Eastern and Western countries. Methods: This study included 564 patients who underwent living donor liver transplantation (LDLT) in three large-volume hospitals in Ko...
#1Sungwon Chung (SNU: Seoul National University)
#2Jeong-Hoon Lee (SNU: Seoul National University)H-Index: 22
Last.Yun Bin Lee (SNU: Seoul National University)H-Index: 8
view all 10 authors...
#1Young Youn Cho (CAU: Chung-Ang University)H-Index: 9
#2Young Jun Chang (SNU: Seoul National University)H-Index: 19
Last.Yoon Jun Kim (SNU: Seoul National University)H-Index: 36
view all 9 authors...
Background and Goals:Although nonalcoholic fatty liver disease (NAFLD) is a risk factor of hepatocellular carcinoma (HCC), it is unclear whether NAFLD additionally increases the risk of HCC among chronic hepatitis B (CHB) patients. This study evaluated the association between NAFLD and the risk of H
12345678910